Back

The importance of optimal RAASi therapy in heart failure.

27 August 2022 (12:50 - 13:05)
Organised by:
Congress Presentation Part of: Clinical case discussion: the value of optimising RAAS inhibition and preserving normokalemia in heart failure Heart Failure with Reduced Ejection Fraction (HFrEF) Open Access ESC Congress 2022

About the speaker

Photo
Professor Dan Atar

Oslo University Hospital Ulleval, Oslo (Norway)

4 More presentations in this session

Presentation thumbnail
Clinical case presentation of a patient with heart failure.
Professor P. Van Der Meer (Groningen, NL)
Slides Video
Presentation thumbnail
How potassium binders can enable RAASi therapy in heart failure.
Doctor M. Kosiborod (Kansas City, US)
Slides Video
Presentation thumbnail
Practical guidance on use of potassium binders in the management of hyperkalemia in heart failure.
Doctor C. Bonanad Lozano (Valencia, ES)
Slides Video
Presentation thumbnail
Panel discussion.
Professor P. Van Der Meer (Groningen, NL)
Slides Video

Access the full session

Session thumbnail
Clinical case discussion: the value of optimising RAAS inhibition and preserving normokalemia in heart failure
Video

The Event

Event poster

ESC Congress 2022

27 August 2022 12:50 CET
You may be interested in
thumbnail
Congress Presentation
Continuing foundational therapy in symptomatic heart failure: The key role of RAASi-based therapy
20 May 2023
thumbnail
Congress Session
Heart and kidney in heart failure: no end to the dangerous liaison
31 August 2024
thumbnail
Congress Presentation
Hypertension and potassium
30 August 2025
thumbnail
Congress Presentation
Optimisation of renin-angiotensin-aldosterone system inhibitors use in chronic kidney disease patients with heart failure: is hyperkalaemia a barrier?
17 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources